Mobula-IGM

Mobula-IGM is a biotechnology company focused on developing high-avidity IgM antibodies for the treatment of cancer. The company's lead program is an IgM-based agonist targeting the Glucocorticoid-induced TNFR-related protein (GITR), designed to enhance anti-tumor immune responses. By leveraging the unique structural properties of IgM antibodies, which possess ten binding sites compared to the two found in standard IgG antibodies, Mobula-IGM aims to achieve superior receptor clustering and signaling. The company operates as a specialized entity within the broader IgM antibody development space, focusing on optimizing T-cell co-stimulation in the tumor microenvironment.